150 related articles for article (PubMed ID: 2103491)
21. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
22. Cathepsin D: a protease involved in breast cancer metastasis.
Rochefort H; Capony F; Garcia M
Cancer Metastasis Rev; 1990 Dec; 9(4):321-31. PubMed ID: 1965795
[TBL] [Abstract][Full Text] [Related]
23. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
24. [Cathepsin D in diagnosis of neoplastic diseases].
Warwas M; Taurowska E
Postepy Hig Med Dosw; 1993; 47(4):277-88. PubMed ID: 8309853
[TBL] [Abstract][Full Text] [Related]
25. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis.
Liaudet-Coopman E; Beaujouin M; Derocq D; Garcia M; Glondu-Lassis M; Laurent-Matha V; Prébois C; Rochefort H; Vignon F
Cancer Lett; 2006 Jun; 237(2):167-79. PubMed ID: 16046058
[TBL] [Abstract][Full Text] [Related]
26. Cathepsin-D in human breast cancer: correlation with vascular invasion and other clinical and histopathological characteristics.
Hähnel R; Harvey J; Robbins P; Sterrett G
Anticancer Res; 1993; 13(6A):2131-5. PubMed ID: 8297125
[TBL] [Abstract][Full Text] [Related]
27. Characterization and properties of two monoclonal antibodies specific for the Mr 52,000 precursor of cathepsin D in human breast cancer cells.
Freiss G; Vignon F; Rochefort H
Cancer Res; 1988 Jul; 48(13):3709-15. PubMed ID: 2454153
[TBL] [Abstract][Full Text] [Related]
28. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
29. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
Foekens JA; Look MP; Bolt-de Vries J; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Jan; 79(2):300-7. PubMed ID: 9888472
[TBL] [Abstract][Full Text] [Related]
30. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis?
Rochefort H; Capony F; Garcia M; Cavaillès V; Freiss G; Chambon M; Morisset M; Vignon F
J Cell Biochem; 1987 Sep; 35(1):17-29. PubMed ID: 3312245
[TBL] [Abstract][Full Text] [Related]
31. Cathepsin D in the malignant progression of neoplastic diseases (review).
Leto G; Gebbia N; Rausa L; Tumminello FM
Anticancer Res; 1992; 12(1):235-40. PubMed ID: 1567172
[TBL] [Abstract][Full Text] [Related]
32. [Cathepsin D expression in primary breast cancer. Comparison of immunohistochemical and biochemical results].
Göhring UJ; Ingenhorst A; Crombach G; Scharl A
Pathologe; 1993 Dec; 14(6):313-7. PubMed ID: 8121884
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical visualisation of cathepsin-D expression in breast cancer.
Barthell E; Mylonas I; Shabani N; Kunze S; Kuhn C; Jeschke U; Friese K
Anticancer Res; 2007; 27(4A):2035-9. PubMed ID: 17649818
[TBL] [Abstract][Full Text] [Related]
34. Cathepsin D concentration in tumor cytosols improves the accuracy of prognostic evaluation of primary breast cancer.
Ardavanis A; Scorilas A; Amanatidou A; Gerakini F; Missitzis I; Garoufali A; Pissakas G; Pateras C; Apostolikas N; Rigatos G; Yiotis I
Anticancer Res; 1997; 17(2B):1405-9. PubMed ID: 9137506
[TBL] [Abstract][Full Text] [Related]
35. Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters.
Maudelonde T; Khalaf S; Garcia M; Freiss G; Duporte J; Benatia M; Rogier H; Paolucci F; Simony J; Pujol H
Cancer Res; 1988 Jan; 48(2):462-6. PubMed ID: 3275497
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
37. [Significance of cathepsin D in breast cancer].
Rochefort H
Rev Prat; 1990 Mar; 40(9):837-9. PubMed ID: 2320913
[No Abstract] [Full Text] [Related]
38. The immunohistochemical expression of cathepsin D in colorectal cancer.
Valentini AM; Pirrelli M; Armentano R; Caruso ML
Anticancer Res; 1996; 16(1):77-80. PubMed ID: 8615673
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
[TBL] [Abstract][Full Text] [Related]
40. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
